Stem

[thecrow]

sopra 2,15 proverei anche se e' tirata

 

[Your Ffaiper]

sopra 2,15 proverei anche se e' tirata

alla faccia,,,sembra la mia pazienza di oggi

 

[dual]

up

 

[moorecat]

4,80$

 

[thecrow]

4,80$

 

[moorecat]

certo che ci sono delle staminali che stanno soffrendo moltissimo.... quelle degli scopertisti che stranno strizzando per i c.........

Giovnani

 

[Mr China Investiment]

S T I

 

[Fabio.S]

prossima resistenza?

 

[Fabio.S]

cosa ne pensate

 

[valsente]

cosa ne pensate

Low-Priced Stocks. Instinct tells me that StemCells Inc. (Nasdaq: STEM) is going to be a wildly volatile "story" stock that has to be watched every minute, especially now that it's planning a 7.5 million-share stock offering at a price lower than today's. StemCells does research aimed at developing therapies that would use stem and similar cells to treat and possibly one day cure Parkinson's and Alzheimer's diseases, multiple sclerosis, spinal cord injuries, stroke, hepatitis, chronic liver failure and diabetes. StemCells's edge for the time being is that it uses cells derived from fetal or adult tissue sources which at this moment is more or less legal; the company doesn't use embryonic stem cells, which is a type of research that gets no Federal funding yet. The company's third quarter loss widened by 79% to $4.3 million while revenue fell to almost nothing due to less grant money and a sole reliance on licensing agreements.

StemCells is planning to file its first investigative new drug application with the FDA in the first quarter of 2005 for a human neural stem product to treat a fatal neurogenerative disease, which could help the stock. But far sooner than that, companies in this niche could get a huge boost if California's "Prop 71" referendum to raise $3 billion for stem cell research passes next week. If it doesn't pass, it will be merely a temporary setback; given the momentum behind this movement, stem cell research is going to proceed, whether in this country or somewhere else. The stock has fallen back after Monday's intraday high of $4.87 and selling volume appears to be stabilizing. Again, expect volatility, particularly when institutional investors buy those 7.5 million shares at $3. But the stock may be fun to watch and if history is any guide, it could double with ease. Stem cell research is a story worth following and $3.47 a share is a relatively painless way to do it. Set a stop, if you wish to, at $2.14.

 

[moorecat]

il titolo e' spinto dal referendum che swarwy ha proposto in california contemporaneamente alle prossime elezioni previdenziali per finanziare con una caterva di miliardi la ricerca sulle staminali dato che il governo federale per motivi etico religiosi non lo fa. Posto che il referendum verra' sicuramente vinto il problema e' che questi finanziamenti andranno alla ricerca istituzionale - universita' ospedali etc - e non a societa' private come la Stem.

 

[Fabio.S]

tutto il capitale su stem....mi date una mano su come comportarmi oggi

 

[Fabio.S]

dentro a 3,78

 

[domino]

ocio!!!

 

[valsente]

ocio!!!

-15%

 

[valsente]

Qualcuno sa spiegarmi cosa e' successo? OK, Kerry era favorevole alle staminali e Bush contrario. Ma in California e' passato il referendum favorevole di Shwarzy e quindi Stem dovrebbe accedere ai contributi statali notevoli. E allora?

 

[valsente]

up. Urge un parere. Grazie

 

[Fabio.S]

volumi in aumento

 

[Trasparente]

scatenata a 4,2$ con 6 mln di pezzi....

 

[Clau]

Up